Recep Tayyip Erdoğan University Institutional Repository
metadata only
CC BY 4.0
Real-world outcomes of CDK4/6 inhibitors in germline BRCA1/2-mutated hormone receptor-positive, HER2-negative metastatic breast cancer: Turkish oncology group (TOG) study
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer#222651
- Factors influencing oncologists’ decisions for germline BRCA testing and adjuvant therapy selection in HER2-negative early breast cancer.#988621
- Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer#1173850
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)#901504
- Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer#807224
Record · ID 396732
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive